DUBLIN, June 30, 2022 /PRNewswire/ — The report “Pharma Contract Development and Manufacturing Market by Service, End User – Global Forecast to 2029” has been added to from ResearchAndMarkets.com offer.
The pharmaceutical contract development and manufacturing market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029.
After extensive secondary and primary research and in-depth analysis of the market scenario, the report presents the key drivers, restraints, challenges and opportunities of the industry. The growth of the pharmaceutical contract development and manufacturing market is majorly attributed to the complex manufacturing requirements, expiring patents, increasing investment in pharmaceutical R&D, inclination of the pharmaceutical industry towards advanced technologies and the outbreak of the coronavirus pandemic. Additionally, the growing demand for cell and gene therapies and personalized drugs and the growth of the High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-Drug Conjugates (ADC) markets provide significant opportunities for players operating in the development and the manufacture of pharmaceutical contracts. market.
On the basis of services, in 2022, it is estimated that the pharmaceutical manufacturing services segment will account for the largest share due to the growing need to reduce manufacturing costs, the use of advanced technologies and skills for manufacturing , the requirement for high quality bulk manufacturing and the growing demand for generic drugs. However, biologics manufacturing services are expected to be the fastest growing segment over the analysis period due to the adoption of advanced technologies for the production of biologics, the trend of biopharmaceutical companies and pharmaceutical companies to outsource their activities, the increase in applications of monoclonal antibodies (mAbs) and the development of next-generation antibody therapies such as antibody-drug conjugates.
The API manufacturing services segment is expected to dominate the pharmaceutical contract manufacturing services market. The need to reduce the production cost of APIs, initiatives undertaken by pharmaceutical companies such as development of new API manufacturing facilities, investments in API manufacturing services, agreements with other key players for the expansion of API manufacturing services and the growing need to reduce the time required for drug development is expected to drive the growth of this segment.
On the basis of end-user, the large pharma segment is estimated to hold the largest share of the contract pharma development and manufacturing market in 2022. The rising incidence and prevalence of various diseases across the world are generating significant demand for effective drugs and breakthrough biopharmaceuticals and the growing need for advanced processes are the key factors driving the growth of the big pharma segment.
An in-depth analysis of the geographical scenario of the Pharmaceutical Contract Development and Manufacturing Market provides detailed qualitative and quantitative information about the top five geographies (North America, Europe, Asia Pacific, Latin Americaand the Middle East & Africa) as well as coverage of the main countries in each region. North America it is estimated to hold the largest pharmaceutical contract development and manufacturing market share in 2022, followed by Europe, Asia Pacific, Latin Americaand the Middle East & Africa.
The major players operating in the pharmaceutical contract development and manufacturing market are Thermo Fisher Scientific Inc. (USA), Catalent Inc. (USA), Lonza Group Ltd (Swiss), Recipharm AB (Sweden), Vetter Pharma-Fertigung GmbH & Co. KG (Germany), Piramal Enterprises Limited (India), Almac Group (UK), Cambrex Corporation (USA), Samsung Biologics Co., Ltd (South Korea), Siegfried Holding AG (Swiss), FUJIFILM Diosynth Biotechnologies (Japan), Aenova Group GmbH (Germany), WuXi Biologics (Cayman) Inc. (China) and Aurobindo Pharma Ltd (India), among others.
Main topics covered:
2. Research methodology
3. Executive Summary
4. Market Overview
4.2.1. Complex manufacturing requirements of the pharmaceutical industry and the growing tendency of manufacturers to use advanced technologies
4.2.2. Growing demand for generic drugs and biologics
4.2.3. Patent expiry
4.2.4. Increase investments in pharmaceutical R&D
4.2.5. Outbreak of the COVID-19 pandemic
4.3.1. Shortage of qualified professionals
4.3.2. Introduction of serialization
4.4.1. Growing demand for cell therapies, gene therapies and personalized medicines
4.4.2. Growing High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-Drug Conjugates (ADC) Markets
4.5. Industry trends
4.5.1. Virtual business models
4.5.2. Growing Consolidation Among CDMO Market Players
5. Pharmaceutical Contract Development and Manufacturing Services Market, By Type
5.2. Pharmaceutical manufacturing services
5.2.1. Active Pharmaceutical Ingredient (API) Manufacturing Services
5.2.2. Finished Dosage Form (FDF) Manufacturing Services
126.96.36.199. Parenteral/Injectables Manufacturing Services
188.8.131.52. Tablet Manufacturing Services
184.108.40.206. Capsule manufacturing services
220.127.116.11. Oral Liquid Manufacturing Services
18.104.22.168. Other formulations
5.3. Drug Development Services
5.4. Biologics Manufacturing Services
5.4.1. Active Pharmaceutical Manufacturing Services (API) Manufacturing Services
5.4.2. Finished Dosage Form (FDF) Manufacturing Services
6. Pharmaceutical Contract Development and Manufacturing Market, By End User
6.2. Big Pharma
6.3. Small and medium pharmaceutical companies
6.4. Generic pharmaceutical companies
7. Pharmaceutical Contract Development and Manufacturing Market, By Geography
7.2. North America
7.3.6. Rest of Europe (Deer)
7.4. Asia Pacific
7.4.4. Rest of Asia Pacific (ROAPAC)
7.5. Latin America
7.5.3. Rest of Latin America
7.6. Middle East & Africa
8. Competitive landscape
8.2. Main growth strategies
8.3. Competitive Benchmarking
8.4. Market Share Analysis (2021) – TOP 19 Players
8.4.1. Lonza Group Ltd. (Swiss)
8.4.2. Catalent INC. (United States)
8.4.3. Thermo Fisher Scientific Inc. (United States)
8.4.4. Samsung Biologics Co., Ltd. (South Korea)
8.4.5. Recipharm AB (Sweden)
9. Company Profiles (Business Overview, CDMO Facilities, Financial Overview, Service Portfolio, Strategic Developments)
9.1. Cambrex Corporation
9.2. Samsung Biologics Co., Ltd.
9.3. Siegfried Holdings AG
9.4. FUJIFILM Diosynth Biotechnologies
9.5. Aenova Group
9.6. Wuxi Biologics, Inc.
9.7. Aurobindo Pharma, Ltd.
9.8. Vetter Pharma international GmbH
9.9. ThermoFisher Scientific, Inc.
9.10. Catalent, Inc.
9.11. Recipharm AB
9.12. Almac Group
9.13. Lonza Group Ltd.
9.14. Piramal Enterprises Limited
9.15. Fabbrica Italiana Sintetici SpA
9.16. Fareva SA
9.17. CH Boehringer Sohn Ag & Co. KG.
9.18. Jubilant Pharmova Limited
9.19. Curia Global, Inc.
For more information about this report, visit https://www.researchandmarkets.com/r/4aux16
Research and Markets
For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716
View original content: https://www.prnewswire.com/news-releases/insights-on-the-pharmaceutical-contract-development–manufacturing-global-market-to-2029— growing-demand-for- cell-therapies-gene-therapies-and-personalized-drugs-301578768.html
SOURCE Research and Markets